Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Onur Baser"'
Autor:
Krishnan Ramaswamy, Onur Baser, Daniel J. George, Megan Ann McNamara, Li Wang, Jack Mardekian, Stanislav Lechpammer, Stephen J. Freedland, Ahong Huang, Neil M. Schultz
Publikováno v:
Journal of Clinical Oncology. 37:212-212
212 Background: Prostate cancer (PC) is the most common malignancy among US men and the 2nd leading cause of cancer-related death. African Americans (AAs) have higher mortality from mCRPC than Whites (W). Despite this disparity, a small prior study s
Autor:
Stanislav Lechpammer, Onur Baser, Krishnan Ramaswamy, Jack Mardekian, Stephen J. Freedland, Neil M. Schultz, Li Wang, Ahong Huang, Daniel J. George
Publikováno v:
Journal of Clinical Oncology. 37:211-211
211 Background: Prostate-Specific Antigen Doubling Time (PSADT) can help predict prostate cancer (PC) patient outcomes, particularly in hormone sensitive disease. However, PSADT has not been well validated in non-metastatic castration-resistant (nmCR
Publikováno v:
Journal of Clinical Oncology. 36:194-194
194 Background: Despite improved survival with advanced multiple myeloma (MM) treatments (Tx), 15–20% of pts experience early relapse. We assessed the economic impact of early progression among non-stem-cell transplant NDMM pts. Methods: NDMM pts w
Publikováno v:
Journal of Clinical Oncology. 36:e20040-e20040
e20040Background: Despite advancements in Multiple Myeloma (MM) treatment (Tx), 10-15% patients (pts) experience early relapse. We assessed the economic impact of early progression in newly diagnos...
Publikováno v:
Journal of Clinical Oncology. 35:e18161-e18161
e18161 Background: The type and place of treatment in relapsed AML has not been explored in a large national data set. The goal of this study is to examine treatment patterns among elderly patients (pts) with relapsed AML. Methods: Elderly pts (age
Publikováno v:
Journal of Clinical Oncology. 35:156-156
156 Background: The outcomes of pts receiving first-line CT vs AT for mCRPC are unclear. Using the VHA dataset, we compared outcomes with first-line CT vs AT in pts with mCRPC and assessed the impact of prior androgen deprivation therapy (ADT) durati
Autor:
Onur Baser, Ravinder Dhawan, Li Wang, Jyotsna Mehta, Diana I. Brixner, Jennifer Sung, Raymond Miao
Publikováno v:
Journal of Clinical Oncology. 32:e16014-e16014
e16014 Background: In April 2011, the FDA approved abiraterone acetate (AA) for the treatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy (ctx),...
Publikováno v:
Journal of Clinical Oncology. 31:204-204
204 Background: Brain metastases (BM) occur in approximately 15-25% of patients with advanced primary cancers and cause significant morbidity and mortality. This study examines the variation in patterns of healthcare and survival among patients with
Publikováno v:
Journal of Clinical Oncology. 31:e16080-e16080
e16080 Background: Corticosteroids (CS) have been integral in metastatic castration-resistant prostate cancer (mCRPC) treatment and can be used alongside life-extending therapies (LETs), despite potential toxicity effects. LET and CS timing and adher
Publikováno v:
Journal of Clinical Oncology. 31:e12010-e12010
e12010 Background: While a breast cancer diagnosis is common in many medical settings, it is still uncommon in the U.S. Department of Veterans Affairs (VA) population, namely due to the minority of female veterans and infrequent diagnosis among men (